Kezar Life Sciences (NASDAQ:KZR – Get Free Report)‘s stock had its “neutral” rating reiterated by stock analysts at HC Wainwright in a research note issued on Monday, Benzinga reports.
Kezar Life Sciences Stock Down 0.7 %
Shares of Kezar Life Sciences stock opened at $0.85 on Monday. Kezar Life Sciences has a 12-month low of $0.52 and a 12-month high of $1.14. The firm has a market capitalization of $61.71 million, a PE ratio of -0.61 and a beta of 0.21. The company has a quick ratio of 9.58, a current ratio of 9.58 and a debt-to-equity ratio of 0.05. The stock’s fifty day moving average is $0.63 and its 200-day moving average is $0.69.
Kezar Life Sciences (NASDAQ:KZR – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. Equities analysts anticipate that Kezar Life Sciences will post -1.2 earnings per share for the current year.
Hedge Funds Weigh In On Kezar Life Sciences
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Featured Stories
- Five stocks we like better than Kezar Life Sciences
- Following Congress Stock Trades
- 3 Stocks Under $20 for Buy-and-Hold Investors Seeking Growth
- 3 REITs to Buy and Hold for the Long Term
- BlackRock’s Earnings Reveal Market Shift: Why Bonds Are in Favor
- What are earnings reports?
- JPMorgan Can Hit New Highs This Year: Here’s Why
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.